Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0552W HIGH $3.55
Volume
20.60 K
Value Traded
62.78 K
Short % Float
1.18%
-2.8%Week
-48.33%1 Month
-20.11%3 Month
-16.77%6 Month
-97.1%5 Year
-99.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.07 M
EPS (TTM)
-4.27
P/E Ratio
-
Ent. Value
-22.63 M
Total Shares
7.25 M
Float Shares
6.92 M
Insiders
4.53%
Institutions
5.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CMMB Catalyst Timeline
Dated clinical, regulatory and corporate events for Chemomab Therapeutics Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Chemomab Therapeutics Ltd.
171Total events
12Upcoming
34Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Poster PresentationnebokitugPresentation
Presented three abstracts at EASL 2026
primary sclerosing cholangitissource ↗
▲Oral PresentationnebokitugPresentation
Oral presentation of new SPRING trial data at DDW 2026
primary sclerosing cholangitissource ↗
◆Oral PresentationPresentation
Corporate presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲PublicationnebokitugPresentation
Phase 2 SPRING trial results published in American Journal of Gastroenterology
primary sclerosing cholangitissource ↗
▲Full ResultsnebokitugClinical Data
Phase 2 SPRING trial results published in American Journal of Gastroenterology
Primary Sclerosing Cholangitis (PSC)source ↗
▲FDA Feedback ReceivednebokitugFDA Meeting
FDA positive feedback on Phase 3 design near completion
primary sclerosing cholangitis (PSC)source ↗
▲EU MAA SubmissionnebokitugEx-US Regulatory
EMA guidance supporting single Phase 3 registration trial using clinical event composite endpoint
primary sclerosing cholangitis (PSC)source ↗
▲Oral PresentationnebokitugPresentation
New clinical data on nebokitug's direct macrophage-mediated mechanisms presented at AASLD 2025
primary sclerosing cholangitis (PSC)source ↗
◆Poster PresentationnebokitugPresentation
Poster #4396: Safety and activity of nebokitug over 48 weeks in PSC: OLE results from SPRING
primary sclerosing cholangitissource ↗
▲Poster PresentationnebokitugPresentation
Three poster presentations at AASLD The Liver Meeting 2025
Primary Sclerosing Cholangitis (PSC)source ↗
◆Oral PresentationPresentation
Corporate presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Oral PresentationnebokitugPresentation
Oral presentation at BSG Live'25 awarded Best Oral Presentation
Primary Sclerosing Cholangitis (PSC)source ↗
▲Oral PresentationnebokitugPresentation
Oral presentation of Phase 2 SPRING trial data at BSG Live'25
primary sclerosing cholangitissource ↗
◆Oral PresentationnebokitugPresentation
Oral presentation at BSG Live'25: CM-101 results from SPRING study in PSC
primary sclerosing cholangitissource ↗
▲End Of Phase 2 MeetingnebokitugFDA Meeting
FDA End-of-Phase 2 meeting with CMC alignment
primary sclerosing cholangitissource ↗
▲Type C MeetingnebokitugFDA Meeting
FDA Type C meeting agreement on non-clinical toxicology parallel conduct
primary sclerosing cholangitissource ↗
▲FDA Feedback ReceivednebokitugFDA Meeting
FDA agreement on CMC strategy and parallel toxicology testing
Primary Sclerosing Cholangitis (PSC)source ↗
▲Patent GrantednebokitugIP / Competition
Patent granted in Russia for method of treatment using anti-CCL24 antibodies
hepatic diseases including primary sclerosing cholangitissource ↗
◆Poster PresentationnebokitugPresentation
Poster presentation at EASL 2025: CCL24 blockade alters the proteomic profile of PSC patients
primary sclerosing cholangitissource ↗
◆Poster PresentationnebokitugPresentation
Poster presentation at EASL 2025: CM-101 PK/PD in PSC
primary sclerosing cholangitissource ↗
▲Oral PresentationnebokitugPresentation
Oral Distinguished Abstract Plenary at DDW 2025
Primary Sclerosing Cholangitis (PSC)source ↗
▲Oral PresentationnebokitugPresentation
Positive Phase 2 SPRING trial data presented at DDW 2025 Distinguished Abstract Plenary session
primary sclerosing cholangitissource ↗
▲Topline ReadoutnebokitugClinical Data
Topline data from Phase 2 SPRING trial presented at DDW 2025
primary sclerosing cholangitissource ↗
▲Poster PresentationnebokitugPresentation
Two posters at EASL 2025 on proteomic and PK/PD analyses
Primary Sclerosing Cholangitis (PSC)source ↗
●Management ChangeCorporate
Appointment of Interim CMO and promotion of Chief Development Officer
▲Trial CompletionnebokitugTrial
Phase 2 SPRING trial in PSC successfully completed
primary sclerosing cholangitis (PSC)source ↗
●Oral PresentationnebokitugPresentation
SPRING trial data presented at multiple major scientific meetings
primary sclerosing cholangitissource ↗
▲FDA Feedback ReceivednebokitugFDA Meeting
FDA alignment on CMC and non-clinical toxicology regulatory path forward
primary sclerosing cholangitissource ↗
▲Full ResultsnebokitugClinical Data
Positive results from Open Label Extension of Phase 2 SPRING trial
primary sclerosing cholangitis (PSC)source ↗
●Oral PresentationnebokitugPresentation
OLE results available on company website
primary sclerosing cholangitis (PSC)source ↗
●Oral PresentationnebokitugPresentation
Scientific presentation at CORA 2025
systemic sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How CMMB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-10 | Nebokitug (first-in-class antibody that inhibits the soluble protein CCL24) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 90%
Micro Cap(rank 592 of 658)
Percentile Rank
Chemomab Therapeutics Ltd. faces pipeline headwinds (22/100), with $190M risk-adjusted pipeline value, led by Anti-human CCL24 monoclonal antibody in Healthy (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-human CCL24 monoclonal antibody Monoclonal antibodyCompletedNCT04595825 | Primary Sclerosing Cholangitis | Phase 2 | COMPLETED | 77 | Jan 10, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every CMMB program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cohen Neil HarrisDirector | Sell | -1,000 33,000 held | $2.80 | 08/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CMMB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 81.00 K | 51.79 K |
CMMB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CMMB ranks across every disease it competes in
Competitive Position is a premium feature
See how CMMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCMMB News
CMMBChemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
Chemomab Therapeutics will present at the H.C. Wainwright 28th Annual Global Investor Conference, with CEO Dr. Adi Mor delivering a prerecorded presentation. The company is advancing its anti-CCL24 antibody, nebokitug, into a Phase 2 trial for rheumatoid arthritis. This follows a merger agreement with Scipher Medicine, expected to close by year-end.
Read more →CMMB▲ +9.4%on this news
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Chemomab Therapeutics has announced its second quarter 2026 financial results and provided an update on its proposed merger with Scipher Medicine. The merger aims to advance nebokitug, a novel therapy for rheumatoid arthritis, with a Phase 2 trial expected to start in H1 2027. The combined entity is valued at $150 million and will focus on addressing significant unmet needs in immunology-based diseases.
Read more →CMMB▼ -28.9%on this news· ran to -40% by day 3
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab Therapeutics and Scipher Medicine have announced a merger to advance nebokitug, an anti-CCL24 antibody, through a Phase 2 trial for rheumatoid arthritis. The merger is supported by a $30 million financing commitment and aims to leverage Scipher's AI platform for patient selection. The combined company will operate under the name Scipher Medicine Corporation and is expected to close in Q4 2026, pending shareholder approvals.
Read more →CMMBChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported its Q1 2026 financial results, highlighting advancements in its nebokitug program for primary sclerosing cholangitis (PSC). New clinical data presented at major medical meetings indicates nebokitug's potential as a disease-modifying treatment, particularly for PSC patients with co-existing inflammatory bowel disease (IBD). The company is actively pursuing strategic partnerships and has a solid cash position to support ongoing operations.
Read more →CMMBChemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Chemomab Therapeutics (NASDAQ: CMMB) reported its financial results for the year and fourth quarter ending December 31, 2025, highlighting significant progress in its nebokitug program for primary sclerosing cholangitis (PSC). The company successfully navigated an FDA End-of-Phase 2 meeting, establishing a clear pathway toward a potential Phase 3 clinical trial. Key achievements from the year included positive SPRING trial results, several scientific presentations that underscored nebokitug's therapeutic potential, and ongoing discussions with strategic partners to advance the program. These developments may ultimately lead to nebokitug becoming the first approved therapy for PSC and other fibro-inflammatory conditions.
Read more →CMMBChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Chemomab Therapeutics will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Dr. Adi Mor and the senior management team will present and engage in one-on-one investor meetings. The company is known for its innovative therapies targeting fibro-inflammatory diseases, particularly its monoclonal antibody nebokitug, which has shown promising results in clinical trials.
Read more →CMMBChemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Chemomab Therapeutics announced the publication of results from its Phase 2 SPRING trial assessing nebokitug in primary sclerosing cholangitis (PSC). The study indicated that nebokitug was safe and well-tolerated for up to 48 weeks, with notable improvements in inflammation and fibrosis biomarkers, especially at the 20 mg/kg dose. These promising results support the initiation of a Phase 3 trial, which aims to further evaluate nebokitug's efficacy in treating PSC, a disease currently without adequate treatment options.
Read more →CMMBChemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) will participate in Oppenheimer's Movers in Rare Disease Summit on December 11, 2025. CEO Adi Mor will present a corporate overview and engage in one-on-one meetings with investors. The company is notably advancing nebokitug, a monoclonal antibody designed to treat fibro-inflammatory diseases, which has shown positive results in clinical trials and received favorable regulatory designations from the FDA and EMA. This summit marks an important opportunity for Chemomab to strengthen investor relations and discuss their innovative therapeutic developments.
Read more →CMMB▼ -10%on this newsshared move
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported positive developments regarding its nebokitug Phase 3 trial for primary sclerosing cholangitis (PSC). The company received favorable feedback from the FDA and EMA, indicating that a single registration trial could suffice for approval. Recent data presented at AASLD 2025 highlighted nebokitug's potential to modify disease progression in PSC patients. Chemomab is also exploring partnerships to support the trial's advancement.
Read more →CMMBChemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Chemomab Therapeutics announced that new clinical data from the Phase 2 SPRING trial of nebokitug will be presented at AASLD The Liver Meeting 2025. The data indicates that nebokitug has shown favorable safety and consistent improvements in key biomarkers in patients with primary sclerosing cholangitis (PSC). The company aims to initiate a Phase 3 trial based on these promising results.
Read more →CMMBChemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Chemomab Therapeutics announced that CEO Dr. Adi Mor will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will be available via webcast on September 5, 2025. The company is also hosting one-on-one investor meetings during the conference. Chemomab's lead product, nebokitug, has shown positive results in clinical trials and is preparing for a Phase 3 trial in primary sclerosing cholangitis.
Read more →CMMB▼ -6.3%on this news
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics has reported its financial results for Q2 2025, highlighting progress in the Phase 3 program for nebokitug, aimed at treating primary sclerosing cholangitis (PSC). The company is actively seeking strategic partnerships to enhance development resources and has aligned with the FDA on regulatory requirements. Additionally, Chemomab plans to adjust its American Depositary Shares ratio, effective August 26, 2025.
Read more →CMMBChemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
Chemomab Therapeutics presented positive Phase 2 SPRING trial data for nebokitug in primary sclerosing cholangitis (PSC) at BSG Live'25. The treatment demonstrated a favorable safety profile and significant improvements in biomarkers associated with PSC progression. The findings support the advancement of nebokitug to a Phase 3 trial, aiming to address the unmet need for effective PSC therapies.
Read more →CMMB▼ -7.5%on this news
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
Chemomab Therapeutics has received positive feedback from the FDA regarding its Phase 3 development program for nebokitug, a treatment for primary sclerosing cholangitis (PSC). The FDA agreed on the Chemistry, Manufacturing, and Controls (CMC) strategy and allowed non-clinical toxicology studies to proceed concurrently with the clinical trial. This advancement supports Chemomab's efforts to finalize the trial details and engage with strategic partners.
Read more →CMMBChemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
Chemomab Therapeutics has received new patent protections for its drug nebokitug in China and Russia, enhancing its intellectual property portfolio. The drug is positioned to potentially become the first approved treatment for primary sclerosing cholangitis (PSC), following positive results from the Phase 2 SPRING trial. The FDA has also outlined a clear pathway for regulatory approval, which is a significant milestone for the company.
Read more →CMMB▲ +6.6%on this news
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported its financial results for Q1 2025 and highlighted significant milestones for its lead candidate, nebokitug. The company achieved a clear regulatory pathway with the FDA for a Phase 3 trial aimed at treating primary sclerosing cholangitis (PSC). Positive data from the SPRING trial showed that nebokitug improved key biomarkers in patients with moderate/advanced PSC. Chemomab's cash position is robust, extending its runway into the second quarter of 2026, and it is exploring partnership options to advance its clinical program.
Read more →CMMB▼ -6.3%on this news
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
Chemomab Therapeutics has presented promising Phase 2 data for its drug nebokitug in treating primary sclerosing cholangitis (PSC) at DDW 2025. The trial demonstrated that nebokitug is well-tolerated and showed significant improvements in various biomarkers related to disease progression over 48 weeks. This encouraging data has prompted the company to advance nebokitug to a Phase 3 study, reflecting its potential as a first-in-class treatment for PSC, a disease with currently no FDA-approved therapies.
Read more →CMMBChemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
Chemomab Therapeutics has announced promising clinical data for its treatment, nebokitug, at EASL 2025. The analysis from the Phase 2 SPRING trial indicates significant and dose-dependent improvements in various biomarkers associated with primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases. Furthermore, pharmacokinetic data demonstrates effective engagement between nebokitug and its target, CCL24, suggesting a robust clinical potential for the therapy in treating PSC. The data will be presented at the upcoming EASL congress in Amsterdam.
Read more →CMMBChemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
Chemomab Therapeutics announced that it will present clinical data on nebokitug (CM-101) for primary sclerosing cholangitis at major upcoming scientific conferences. The company has reported positive results from previous trials and is preparing for a Phase 3 trial based on its Phase 2 SPRING trial outcomes. Nebokitug has received Orphan Drug and Fast Track designations from regulatory authorities.
Read more →CMMBChemomab Announces New Medical and Clinical Appointments
Chemomab Therapeutics has announced the appointment of David M. Weiner, MD, as Interim Chief Medical Officer and Jack Lawler as Chief Development Officer. Weiner returns to the company with extensive experience in drug development, while Lawler has been pivotal in the successful Phase 2 SPRING trial for their product nebokitug. The company anticipates a smooth transition as it plans the next steps following the trial's success. However, there are inherent risks in obtaining regulatory approval and market acceptance for nebokitug.
Read more →About Chemomab Therapeutics Ltd.
HeadquartersKIRYAT ATIDIM, BUILDING 7, TEL AVIV, L3, 6158002
BIOPHARMAWATCH ELITE PLUS
Trade the next CMMB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime